Skip to main content

Table 2 Comorbidities among Covid-19 patients admitted for treatment. The number and percentage of patients for each variable are provided in columns “survivor” and “non-survivor”. The P values is are based on comparisons between “survivor” and “non-survivor” patients. CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease

From: Higher comorbidities and early death in hospitalized African-American patients with Covid-19

Comorbidities All Patients
no./total (%)
Survivors
no. (%)
Non-survivors no. (%) Odds Ratio
(95% CI)
P value
Asthma 30/475 (6) 9 (30) 21 (70) 2.77 (1.18–7.04) 0.01
Autoimmune disease 37/495 (7) 22 (59) 15 (41) 0.71 (0.33–1.47) 0.39
History of cancer 43/496 (9) 14 (33) 29 (67) 2.39 (1.18–5.03) 0.010
COPD 36/481 (7) 16 (44) 20 (56) 1.48 (0.71–3.16) 0.297
Coronary Artery Disease 42/529 (8) 10 (24) 32 (76) 3.77 (1.76–8.81) < 0.001
Congestive Heart Failure 25/529 (5) 16 (64) 9 (36) 0.59 (0.22–1.45) 0.22
CKD without dialysis 73/504 (14) 28 (38) 45 (62) 1.88 (1.11–3.27) 0.016
CKD with dialysis 11/504 (2) 9 (81) 2 (18) 0.23 (0.02–1.14) 0.06
ESRD on dialysis 50/504 (10) 34 (68) 16 (32) 0.47 (0.23–0.90) 0.02
Diabetes mellitus 289/517 (56) 139 (48) 150 (52) 1.48 (1.03–2.13) 0.03
Hyperlipidemia 82/529 (16) 34 (42) 48 (58) 1.63 (0.98–2.72) 0.05
Hypertension 416/517 (79) 212 (51) 204 (49) 1.35 (0.85–2.15) 0.184
Immune suppression 25/489 (5) 17 (68) 8 (32) 0.48 (0.17–1.21) 0.102
All patients
≥ 1 Comorbidities
517/529 (98) 271 (99) 246 (96)
\